Skip to main content
All lobbying filings

CENCORA, INC.

CENCORA, INC. filed a Q4 report for CENCORA, INC. on January 20, 2026.

Lobbying for CENCORA, INC.

All filings by CENCORA, INC. · Everything CENCORA, INC. has reported

 Filing · LD-2 quarterly report Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Expenses
$1,910,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5
Medicare/Medicaid

Ensuring Community Access to Pharmacist Services Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act (S.2426) Inflation Reduction Act implementation, including impact on Pharmacy & Physician Reimbursement Extend payment increase under Medicare's physician fee schedule. Medicare Access & CHIP Reauthorization Act (MACRA). Protecting Patient Access to Cancer and Complex Therapies Act 2025 (H.R.4299) Reimbursement policies impacting drug shortages Part B drug pricing changes Enhanced Oncology Model (EOM) Preventing and Mitigating Generic Drug Shortages CMS Proposed Medicare Physician Fee Schedule Rule Proposed Changes to Bonafide Service Fees

Pharmacy

Preventing and Mitigating Generic Drug Shortages Ensuring Seniors Access to Critical Medications Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act (S.2426)- Impacts to pharmacy Part D drug pricing in Inflation Reduction Act (IRA)

Health Issues

Strategic National Stockpile Essential Medicines Strategic Stockpile Department of Defense Essential Medicines Strategic Stockpile Prescription Information Modernization Act (H.R.4132/S.2027) Mitigation of Drug Shortages Pharmaceutical supply chain resilience Pandemic and All Hazards Preparedness Reauthorization and Response Act (legislation). SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R. 2483/S.2121) Medical Supply Resiliency Act (H.R. 2231) National Defense Authorization Act FY2026 (NDAA) Supply Chain Resiliency Most Favored Nation drug pricing proposals CMS Proposed Medicare Physician Fee Schedule Rule

Taxation/Internal Revenue Code

Global Intangible Low-taxed Income (GILTI) Last in First Out (LIFO) accounting method

Trade (domestic/foreign)

Tariff proposed policies

 Bills named in this filing 8
  • H.R. 3164
    Ensuring Community Access to Pharmacist Services Act
  • S. 2426
    Equitable Community Access to Pharmacist Services Act
  • H.R. 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • H.R. 4132
    Prescription Information Modernization Act of 2025
  • S. 2027
    Prescription Information Modernization Act of 2025
  • H.R. 2483
    SUPPORT for Patients and Communities Reauthorization Act of 2025
  • S. 2121
    SUPPORT for Patients and Communities Reauthorization Act of 2025
  • H.R. 2231
    Motorsports Fairness and Permanency Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem